Systemic anti-cancer therapy: An expert guide

Written in association with: Professor Andrew Wardley
Published: | Updated: 02/05/2023
Edited by: Sophie Kennedy

At the forefront of cancer therapy, systemic anti-cancer treatment (SACT) is offering improved outcomes and fewer side effects for patients. In this informative article, highly respected consultant medical oncologist Professor Andrew Wardley shares his expert insight on systemic anti-cancer therapy, what it involves and how it relates to treatment of breast cancer.

 

What is systemic anti-cancer therapy?

Systemic anti-cancer therapy (SACT) is a term that has replaced ‘chemotherapy as many new treatments have considerably fewer side-effects and better efficacy. They target and destroy cancer cells throughout the body. SACT includes chemotherapy, hormonal therapy, immunotherapy, and targeted therapies.

 

When is systemic anti-cancer therapy indicated, and how is it given?

Systemic anti-cancer therapy is indicated for patients with cancer that has spread beyond the primary site, or for those at high risk of the cancer returning after surgery or radiation therapy; this is because there has been spread of many cancers that is undetectable at the time of diagnosis. Most cancers require some form of SACT. It may be given as tablets, injections or intravenous infusion.

 

How does SACT work? How is SACT used to treat breast cancer treatment?

Systemic anti-cancer therapy works by killing and inhibiting the growth and spread of cancer cells. Chemotherapy, for example, uses drugs that target rapidly dividing cells, which cancer cells are. Understanding cancer biology has helped us to develop treatments that target cancers according to the cancer’s biology. Treatments are tailored to the individuals’ cancer; precision medicine allowing personalised medicine.

 

The main treatments for breast cancer include:

  • Hormonal therapy blocking the oestrogen that fuels the growth of certain types of cancer
  • Targeted therapies that target the key drivers of growth such as HER-2
  • CDK4/6 inhibitors targeting the cell mechanisms for cancer growth
  • Immunotherapy which helps the body's immune system recognise and attack cancer cells

 

What are the side effects of systemic anti-cancer therapy?

The side effects of systemic anti-cancer therapy can vary depending on the type of treatment and the individual patient. Common side effects include fatigue, nausea, hair loss, and an increased risk of infection. Hormonal therapy can also cause hot flashes, night sweats, and vaginal dryness. Targeted therapy can cause skin rashes, diarrhoea, and changes in liver function. Immunotherapy can cause inflammation in various parts of the body, such as the lungs, liver, and gut.

It is important to discuss any side effects with your healthcare provider and to report any severe or persistent side effects as soon as possible.

 

If you are seeking treatment for breast cancer and wish to schedule a consultation with Professor Wardley, you can do so by visiting his Top Doctors profile.

By Professor Andrew Wardley
Medical oncology

Professor Andrew Wardley is an internationally-renowned consultant medical oncologist and breast cancer specialist with practice across the UK with Sciensus (Healthcare at Home), who specialises in the diagnosis, treatment and integrated care of breast cancer. His expertise in breast cancer research, innovation and transformation has enabled him to ensure that the multiple international clinical trials he has led throughout his career, have been adopted in clinical practice to improve the outcomes and the experience of people with breast cancer. Professor Wardley currently sees patients at HCA – Leaders in Oncology Care and at Sciensus – Cancer at home. He has extensive experience using system leadership for service innovation.

Professor Wardley believes in research-driving care; ‘a question to answer for every person’. He conceived, developed and led a fully-integrated, patient-focused, research-centred, holistic breast cancer service that directly improves patient care and access to novel treatments. This integrated cancer care system, introduced in Greater Manchester in 2001, has been adopted by NHS England and the European Code of Cancer Practice. In 2020, Professor Wardley founded Outreach Research and Innovation Group to continue developing this model further.

Professor Wardley was a major driver to developing cancer research and services in Greater Manchester and Cheshire, creating collaborative partnerships with international research groups and pharma. He co-founded Manchester Breast Centre and helped to design and develop Manchester Cancer Research Centre, Manchester Academic Health Science Centre and Greater Manchester Cancer. His collaborative approach was also instrumental in forming NIHR Manchester Clinical Research Facility, a key factor in a successful NIHR Biomedical Research Centre bid and CRUK Major Centre and Manchester Academic Health Science Centre funding.

Professor Wardley has educated two generations of medical oncologists and breast cancer specialists through education schemes from the European Society of Medical Oncology, the European School of Oncology, the Association of Cancer Physicians and the Royal College of Physicians. He is an active member of various international trial co-operatives.

View Profile

Overall assessment of their patients


  • Related procedures
  • Prostate cancer
    Breast cancer
    Bone cancer
    Nervous system malformations
    Brain tumour
    Bone marrow cancers
    Testicular cancer
    Thyroid cancer
    Adrenal glands cancer
    Neuro-oncology
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.